Zimmer Biomet is a medical devices business based in the US. Zimmer Biomet shares (ZBH) are listed on the NYSE and all prices are listed in US Dollars. Zimmer Biomet employs 18,000 staff and has a trailing 12-month revenue of around $7.5 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $114.48 |
|---|---|
| 52-week range | $101.38 - $133.60 |
| 50-day moving average | $109.79 |
| 200-day moving average | $118.07 |
| Wall St. target price | $126.52 |
| PE ratio | 24.1044 |
| Dividend yield | $0.96 (0.83%) |
| Earnings per share (TTM) | $4.79 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $114.48 from 2024-09-04
| 1 week (2024-08-29) | -0.17% |
|---|---|
| 1 month (2024-08-05) | 6.95% |
| 3 months (2024-06-05) | 1.63% |
| 6 months (2024-03-05) | -8.25% |
| 1 year (2023-09-05) | -2.83% |
|---|---|
| 2 years (2022-09-02) | 8.44% |
| 3 years (2021-09-03) | 146.74 |
| 5 years (2019-09-05) | 137.563 |
Valuing Zimmer Biomet stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zimmer Biomet's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zimmer Biomet's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Zimmer Biomet shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Zimmer Biomet's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6488. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zimmer Biomet's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zimmer Biomet's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 billion.
The EBITDA is a measure of a Zimmer Biomet's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $7.5 billion |
|---|---|
| Operating margin TTM | 20.71% |
| Gross profit TTM | $4.9 billion |
| Return on assets TTM | 4.54% |
| Return on equity TTM | 7.95% |
| Profit margin | 13.25% |
| Book value | $62.18 |
| Market Capitalization | $23.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 12.31% of net profits
Recently Zimmer Biomet has paid out, on average, around 12.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zimmer Biomet shareholders could enjoy a 0.83% return on their shares, in the form of dividend payments. In Zimmer Biomet's case, that would currently equate to about $0.96 per share.
While Zimmer Biomet's payout ratio might seem low, this can signify that Zimmer Biomet is investing more in its future growth.
Zimmer Biomet's most recent dividend payout was on 30 July 2024. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2024 (the "ex-dividend date").
Zimmer Biomet's shares were split on a 103:100 basis on 28 February 2022. So if you had owned 100 shares the day before before the split, the next day you'd have owned 103 shares. This wouldn't directly have changed the overall worth of your Zimmer Biomet shares – just the quantity. However, indirectly, the new 2.9% lower share price could have impacted the market appetite for Zimmer Biomet shares which in turn could have impacted Zimmer Biomet's share price.
Over the last 12 months, Zimmer Biomet's shares have ranged in value from as little as $101.3806 up to $133.603. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zimmer Biomet's is 1.012. This would suggest that Zimmer Biomet's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zimmer Biomet Holdings, Inc. , together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S. E. T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.